High Times
Home > Boards > US Listed > Biotechs >

Rexahn Pharmaceuticals, Inc. (RNN)

RNN RSS Feed
Add RNN Price Alert      Hide Sticky   Hide Intro
Moderator: DorianGray
Search This Board: 
Last Post: 9/18/2018 3:09:41 PM - Followers: 218 - Board type: Free - Posts Today: 0



   
 



   http://www.rexahn.com/cms/    

    http://finance.yahoo.com/q/ks?s=RNN

       

About

Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN) is a clinical stage biopharmaceutical company focused on developing best-in-class therapeutics for the treatment of cancer. Rexahn’s clinical development programs directly target specific proteins that are selectively expressed in human cancer cells, resulting in increased efficacy and reduced toxicity. In preclinical studies these drug candidates are effective against multiple drug resistant cancers and have shown to increase the effectiveness of various FDA approved cancer treatments. Rexahn is also developing specific biomarker tests that will help identify which patients will be most responsive to its treatments. The Company’s nanotechnology-based drug delivery system has shown it can make FDA approved chemotherapy drugs more effective.

Our clinical development pipeline consists of three novel compounds:

RX-3117 is a novel, oral, small molecule nucleoside compound.  Once intracellularly activated (phosphorylated) by the enzyme UCK2, it is incorporated into the DNA or RNA of cells and inhibits both DNA and RNA synthesis, which induces apoptotic cell death of tumor cells.  Because UCK2 is overexpressed in multiple human tumors, but has a very limited presence in normal tissues, RX-3117 offers the potential for a targeted anti-cancer therapy with an improved efficacy and safety profile, and we believe it has therapeutic potential in a broad range of cancers, including pancreatic, bladder, colon, and lung cancer.  RX-3117 has received “orphan drug designation” from the U.S. Food and Drug Administration (“FDA”) and from the European Commission (“EC”) for pancreatic cancer.

RX-5902 (Supinoxin™) is a potential first-in-class small molecule inhibitor of phosphorylated-p68, a protein that we believe plays a key role in cancer cell growth, progression and metastasis through its interaction with beta-catenin.  Phosphorylated p68, which is highly expressed in cancer cells, but not in normal cells, results in up-regulation of cancer-related genes and a subsequent proliferation of cancer cells and tumor growth.  RX-5902 selectively blocks the interaction of phosphorylated p68 with beta-catenin, thereby decreasing the proliferation or growth of cancer cells in preclinical models.  In addition, multiple pre-clinical models suggest that RX-5902 enhances the efficacy of immunotherapy. We have evaluated RX-5902 in a Phase 1 dose escalation study in patients with a diverse range of metastatic, treatment-refractory tumors, including breast, ovarian, colorectal, and neuro-endocrine tumors.  In February 2017, we initiated a Phase 2a clinical study of RX-5902 in patients with metastatic triple negative breast cancer (“TNBC”).

RX-0201 (Archexin®) is a potential best-in-class, potent inhibitor of the protein kinase Akt-1, which we believe plays a critical role in cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance.  RX-0201 is the subject of a research and development collaboration with Zhejiang Haichang Biotechnology Co., Ltd. (“Haichang”) for the development of RX-0201 for hepatocellular carcinoma. RX-0201 has received orphan drug designation from the FDA for renal cell carcinoma (“RCC”), glioblastoma, ovarian cancer, stomach cancer and pancreatic cancer.

These clinical development programs are part of a growing oncology drug pipeline that consists of highly differentiated and exciting anti-cancer compounds.

Our strategy is to continue building a significant clinical development pipeline of innovative therapies that we will commercialize on our own or with other pharmaceutical partners. Rexahn’s powerful discovery engine and differentiated product pipeline provide the opportunity for a high value generating biopharmaceutical company.

 

 Rexahn  Pipeline

Management Team



Peter Suzdak, Ph.D.
Chief Executive Officer 

Dr. Peter Suzdak joined Rexahn Pharmaceuticals in February 2013. Dr. Suzdak has over 25 years of diverse experience, including several management positions, in the pharmaceutical industry. Most recently, Dr. Suzdak was Chief Scientific Officer of Corridor Pharmaceuticals, a company developing small molecule compounds to treat pulmonary and vascular disorders. Prior to Corridor Pharmacueitcals, he was co-Founder, Chief Executive Officer and Chief Scientific Officer of Cardioxyl Pharmaceuticals, a company focused on therapies for the treatment of cardiovascular disease. Previous to Cardioxyl Pharmaceuticals, he was President and Chief Executive Officer of Artesian Therapeutics, a company engaged in the development of small molecule therapeutics for cardiovascular diseases. Dr. Suzdak’s experience also includes his position as Senior Vice President of Research and Development of Guilford Pharmaceuticals, a company that developed therapeutics and diagnostics for neurological diseases and cancer, and as Director of Neurobiology for Novo Nordisk. Dr. Suzdak holds a Ph.D. in pharmacology and toxicology from the University of Connecticut.

Rick Soni, MBA
President and Chief Operating Officer

Rick Soni joined Rexahn in 2008 with over 20 years of sales, marketing, product planning and business development experience in the pharmaceutical industry. Prior to joining Rexahn, Mr. Soni held leadership roles at Otsuka America Pharmaceuticals, Inc., with responsibility for commercial development, corporate strategy and execution of licensing and acquisition of therapeutics, diagnostics and medical devices. Previously, Mr. Soni has held a variety of management positions at Novartis and Schering-Plough. Mr. Soni has a BS from the University of Wisconsin-Madison and an MBA from Fairleigh Dickinson University.

Tae Heum (Ted) Jeong, D. Mgt.
Sr. Vice President  and Chief Financial Officer

Dr. Jeong has been Chief Financial Officer of Rexahn Pharmaceuticals since 2002. He oversees all aspects of capital raising, accounting, operations, and corporate development for Rexahn. He is also responsible for investor relations, and played a key role in Rexahn’s 2008 listing on the New York Stock Exchange (NYSE) AMEX. For the past 16 years, he has extensive experience in venture capital and investment banking industry that includes role at Hyundai Venture Investment Corporation where he managed the Biotechnology investment team. Dr. Jeong holds a Doctor of Management from University of Maryland and an M.S. in Finance from Johns Hopkins University




ANALYST COVERAGE
 
Roth Capital Partners, LLC
      Joseph Pantginis, Ph.D.
646-358-1907

jpantginis@roth.com

Maxim Group, LLC
Echo He, MD, Ph.D.
212-895-3718

ehe@maximgrp.com

H. C. Wainwright & Co., LLC
Andrew Fein
212-356-0546

afein@hcwco.com   


INVESTOR RELATIONSThe Trout Group LLC
Tricia Truehart
(646) 378-2953
ttruehart@troutgroup.com

High Times
RNN
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
RNN News: Rexahn Pharmaceuticals Presents Preliminary Safety and Efficacy Data From Ongoing Phase 2a Clinical Trial of RX-3117 in Combi... 10/02/2018 08:00:00 AM
RNN News: Rexahn Pharmaceuticals to Present at the 5th NCI Pancreatic Cancer Symposium 09/18/2018 08:00:00 AM
RNN News: Current Report Filing (8-k) 08/30/2018 09:44:35 AM
RNN News: Rexahn Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference 08/30/2018 08:00:00 AM
RNN News: Additional Proxy Soliciting Materials (definitive) (defa14a) 08/22/2018 04:32:21 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#3815  Sticky Note $20 price target - DorianGray 05/19/18 09:49:19 PM
#3832   They r doing another presentation ttubular 09/18/18 03:09:41 PM
#3831   what's all this about today? DorianGray 09/18/18 11:43:06 AM
#3830   Is this what we have been waiting for ttubular 08/21/18 03:10:14 PM
#3829   This little buy rating is giving this a DorianGray 07/31/18 11:53:31 AM
#3828   Totally agreed! It's pretty sad what this stock Crozz 07/23/18 02:06:58 PM
#3827   Management devastated this stock. They had momentum in DorianGray 07/21/18 08:05:29 PM
#3826   The daily volume is pathetic. No real buyers Woulfe 07/20/18 03:55:48 PM
#3825   The balls of this mgmt team. They do Crozz 06/28/18 10:07:14 AM
#3824   Painful - like watching liberals self implode with TDS. DorianGray 06/27/18 11:35:52 AM
#3823   Imminent Q2 catalysts: irule 06/15/18 11:06:49 PM
#3822   IEXG - 121,600 share offering just showed up DorianGray 06/06/18 10:59:42 AM
#3821   looks like I'm always the last one to DorianGray 06/04/18 12:57:12 PM
#3820   The ASCO data summary is already known. Volume Woulfe 05/31/18 12:27:01 PM
#3819   Big ask at 2.26 for 121,600 - not DorianGray 05/31/18 12:08:22 PM
#3818   I get the feeling RNN will run today, DorianGray 05/24/18 11:49:48 AM
#3817   Agreed on the .22. I had not read DorianGray 05/20/18 10:57:29 PM
#3816   Maybe we finally will get real news to ttubular 05/20/18 09:10:50 PM
#3815   $20 price target - DorianGray 05/19/18 09:49:19 PM
#3814   I wonder if this article is fueling the DorianGray 05/19/18 09:40:29 PM
#3813   That's how you finish the day and week....very nice DorianGray 05/18/18 11:25:39 PM
#3812   Things are progressing nicely not very slow. One ttubular 05/16/18 04:44:00 PM
#3811   Rexahn Phase 2a Combination Study of RX-3117 and l2errtx 05/16/18 10:29:54 AM
#3810   https://seekingalpha.com/pr/17163439-rexahn-phase-2a-combination-study-rxminus-3 l2errtx 05/16/18 10:27:55 AM
#3809   Or another head fake. Hard to tell with Woulfe 05/10/18 09:33:26 PM
#3808   Some good news must be coming? ttubular 05/10/18 12:33:33 PM
#3807   moving again on no news - DorianGray 05/10/18 10:12:26 AM
#3806   Some good news must have leaked out. Big ttubular 05/04/18 03:50:24 PM
#3805   it's moving now - some big bids pushing DorianGray 05/04/18 03:45:24 PM
#3804   200MA break bulls trying to push this higher stock1ace1 05/04/18 01:31:23 PM
#3803   Volume is almost 1.5 million today. Something is Woulfe 05/04/18 12:50:51 PM
#3802   covering before earnings? We all know earnings will DorianGray 05/04/18 10:31:37 AM
#3801   well that ended badly - wth..... DorianGray 04/27/18 03:53:40 PM
#3800   Today is a good follow through to yesterdays DorianGray 04/27/18 01:28:40 PM
#3799   Slow study rise the past few days, has Woulfe 04/27/18 01:05:53 PM
#3798   Totally agree with you...... n3m3sis 04/27/18 06:22:01 AM
#3797   This move needs follow up news or another DorianGray 04/26/18 09:43:15 PM
#3796   Not in the public domain.......... n3m3sis 04/26/18 01:59:24 PM
#3795   Today it’s up with high volume. All that’s Woulfe 04/26/18 11:21:55 AM
#3794   50 cent jump in Premarket.... n3m3sis 04/13/18 08:43:58 AM
#3793   Rise up to 1.7 yesterday now back down. Woulfe 04/06/18 01:32:03 PM
#3792   That's what I can't understand, all time lows DorianGray 04/02/18 01:22:33 PM
#3791   At this rate we will be at 10 ttubular 03/28/18 03:06:22 PM
#3790   What’s going on with this one. Another sharp Woulfe 03/27/18 11:51:17 AM
#3789   It's a 10k of jibber jabber, but there DorianGray 03/14/18 01:08:34 AM
#3788   What’s your opinion on the recent 10k filed today? Woulfe 03/09/18 09:51:51 PM
#3787   We were sitting at all time lows, I've DorianGray 03/07/18 10:48:12 PM
#3786   Welcome back to the 1.70’s... volume is picking up. Woulfe 03/07/18 03:29:07 PM
#3785   Heavy volume at the end of the day DorianGray 02/28/18 09:59:45 PM
#3784   Either being heavily manipulated down & will be Woulfe 02/28/18 04:37:15 PM
#3783   I'm a patient person but this is ridiculous, DorianGray 02/28/18 03:30:49 PM
PostSubject